Schott Pharma AG KGaA (WBO:1SXP) ROCE % : 15.89% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Schott Pharma AG KGaA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Schott Pharma AG KGaA's annualized ROCE % for the quarter that ended in Dec. 2024 was 15.89%.

Schott Pharma AG KGaA ROCE % Historical Data

The historical data trend for Schott Pharma AG KGaA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA ROCE % Chart

Schott Pharma AG KGaA Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

25.17

28.34

23.51

22.01

20.92

Schott Pharma AG KGaA Quarterly Data
	Sep20	Sep21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial								25.53	12.49	24.87	20.25	15.89

Schott Pharma AG KGaA ROCE % Calculation

Schott Pharma AG KGaA's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	197.458	/	( ( (1231.828 - 351.146)	+	(1442.269 - 435.48) )	/ 2 )
	=	197.458	/	( (880.682	+	1006.789)	/ 2 )
	=	197.458	/	943.7355
	=	20.92 %

Schott Pharma AG KGaA's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	162.848	/	( ( (1442.269 - 435.48)	+	(1479.646 - 437.355) )	/ 2 )
	=	162.848	/	( ( 1006.789	+	1042.291 )	/ 2 )
	=	162.848	/	1024.54
	=	15.89 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Schott Pharma AG KGaA (WBO:1SXP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Schott Pharma AG KGaA ROCE % Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Schott Pharma AG KGaA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (WBO:1SXP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

1SXPd:UK 1SXP:Germany

Address

Hattenbergstrasse 10, Mainz, RP, DEU, 55122

Website

https://www.schott-pharma.com

Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Schott Pharma AG KGaA Headlines

No Headlines